News & Views Fish Health Recirc Research Shrimp
NaturalShrimp greenlights second phase of freshwater salmon trial

NaturalShrimp has announced its planned funding for a second freshwater salmon trial at the Marineholmen RASLab in Bergen, Norway. In September 2021, the company revealed the initial trial results of its short-term validation study at the Marineholem RASLab, evaluating the effects of using hydrogas technology to increase fish health in recirculating aquaculture systems (RAS).

The positive results initiated a second phase trial, set to take place during the first quarter of 2022, which will include both hydrogas technology and NatrualShrimp’s patented electrocoagulation (EC) technology. If successful, the second phase would provide independent scientifically-validated confirmation of these technologies to improve salmon production.

“In this study, we will investigate the effects of hydrogas on fish welfare and performance in freshwater salmon production,” said Christine Huynh, DMV aquatic species consultant for NaturalShrimp. “The study will include smoltification and transfer into saltwater. We are also including some additional analyses on the microbiome to understand if the negative oxidation reduction potential (ORP) environment influences the consortium of bacteria in RAS.”

NaturalShrimp CEO, Gerald Easterling, continued, “Our initial validation study results demonstrated that fish grown using hydrogas technology had significantly improved welfare scores, fewer inflammatory gill lesions and reduced early maturation, he said. “With these promising early results, we are now focused on proving that hydrogas and our EC technology together, can reduce mortality and increase growth rates for our existing shrimp production.

These platform technologies could be significant breakthroughs for NaturalShrimp because they will enable us to obtain a separate revenue stream through the licensing of these technologies to aquaculture producers of salmon, barramundi, and other freshwater fish.”